 |
市場調査レポート
大腸癌：パイプライン製品の分析Colorectal Cancer - Pipeline Review, H1 2018 |
||||||
| 発行 | Global Markets Direct | 商品コード | 232768 | ||||
| 出版日 | ページ情報 | 英文 2237 Pages  |
|||||
| 価格 |
|
||||||
| 大腸癌：パイプライン製品の分析 Colorectal Cancer - Pipeline Review, H1 2018 | ||
| 出版日: 2018年06月29日 | ページ情報: 英文 2237 Pages |
|
大腸癌は、結腸または直腸から発生し始める癌で、その症状には、下痢や便秘、血便、激しい腹痛、満腹感や膨満感、原因不明の体重減、倦怠感、悪心、嘔吐などがあります。大腸癌を罹患する原因としては、喫煙、2型糖尿病、大腸癌を発症しやすい家系などが挙げられます。
当レポートでは、大腸癌治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H1 2018, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.
Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 27, 132, 157, 16, 185, 32 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 23, 9, 1, 30 and 3 molecules, respectively.
Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
